Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 779,573
  • Shares Outstanding, K 423,681
  • Annual Sales, $ 49,800 K
  • Annual Income, $ -50,340 K
  • EBIT $ -49 M
  • EBITDA $ -47 M
  • 60-Month Beta 0.94
  • Price/Sales 15.91
  • Price/Cash Flow N/A
  • Price/Book 6.32

Options Overview Details

View History
  • Implied Volatility 116.31% (-3.48%)
  • Historical Volatility 55.75%
  • IV Percentile 5%
  • IV Rank 7.53%
  • IV High 434.74% on 05/05/25
  • IV Low 90.38% on 01/20/26
  • Expected Move (DTE 23) 0.3400 (18.58%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 259
  • Volume Avg (30-Day) 482
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 28,746
  • Open Int (30-Day) 33,595
  • Expected Range 1.4900 to 2.1700

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 3
  • High Estimate $-0.03
  • Low Estimate $-0.06
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4900 +22.82%
on 03/30/26
1.9500 -6.15%
on 04/17/26
+0.2700 (+17.31%)
since 03/20/26
3-Month
1.1000 +66.36%
on 01/30/26
1.9500 -6.15%
on 04/17/26
+0.2700 (+17.31%)
since 01/21/26
52-Week
0.5137 +256.24%
on 05/15/25
1.9500 -6.15%
on 04/17/26
+1.2550 (+218.26%)
since 04/21/25

Most Recent Stories

More News
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

 Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...

LXRX : 1.8300 (-0.54%)
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College...

LXRX : 1.8300 (-0.54%)
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential...

LXRX : 1.8300 (-0.54%)
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of...

LXRX : 1.8300 (-0.54%)
Lexicon: Q4 Earnings Snapshot

Lexicon: Q4 Earnings Snapshot

LXRX : 1.8300 (-0.54%)
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase...

LXRX : 1.8300 (-0.54%)
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026...

LXRX : 1.8300 (-0.54%)
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March...

LXRX : 1.8300 (-0.54%)
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the closing of its previously announced underwritten public offering...

LXRX : 1.8300 (-0.54%)
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering...

LXRX : 1.8300 (-0.54%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 1.9833
2nd Resistance Point 1.9367
1st Resistance Point 1.8833
Last Price 1.8300
1st Support Level 1.7833
2nd Support Level 1.7367
3rd Support Level 1.6833

See More

52-Week High 1.9500
Last Price 1.8300
Fibonacci 61.8% 1.4013
Fibonacci 50% 1.2319
Fibonacci 38.2% 1.0624
52-Week Low 0.5137

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.